<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00002180</url>
  </required_header>
  <id_info>
    <org_study_id>269A</org_study_id>
    <secondary_id>GS-96-701</secondary_id>
    <nct_id>NCT00002180</nct_id>
  </id_info>
  <brief_title>A Study of PMPA in HIV-Infected Patients</brief_title>
  <official_title>A Phase I/II Randomized, Double-Blind, Placebo-Controlled Study of the Safety, Tolerance, and Pharmacokinetics, and Antiviral Activity of 9-[(R)-2-(Phosphonomethoxy)Propyl] Adenine (PMPA) in HIV-Infected Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gilead Sciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>NIH AIDS Clinical Trials Information Service</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to see if it is safe and effective to give PMPA to HIV-infected&#xD;
      patients. This study also examines how the body handles PMPA.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <condition>HIV Infections</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tenofovir</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
        Patients must have:&#xD;
&#xD;
          -  Laboratory diagnosis of HIV infection.&#xD;
&#xD;
          -  CD4 cell count &gt;= 200 cells/mm3 within 28 days prior to entry.&#xD;
&#xD;
          -  Plasma HIV RNA &gt;= 10,000 copies/ml within 28 days of entry.&#xD;
&#xD;
          -  Minimum life expectancy of 12 months.&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
        Co-existing Condition:&#xD;
&#xD;
        Patients with any of the following symptoms or conditions are excluded:&#xD;
&#xD;
          -  Active, serious infections (other than HIV) that require parental antibiotic therapy.&#xD;
             Patients may be considered recovered if at least 2 weeks have elapsed following&#xD;
             cessation of parental therapy before enrollment.&#xD;
&#xD;
          -  Active clinically significant medical problems that include cardiac disease (e.g.,&#xD;
             symptoms of ischemia, congestive heart failure, or arrhythmia).&#xD;
&#xD;
          -  Positive test for Hepatitis B surface antigen or Hepatitis C antibody in serum.&#xD;
&#xD;
        Patients with any of the following prior conditions are excluded:&#xD;
&#xD;
        History of malignancy other than basal cell carcinoma or cutaneous Kaposi's sarcoma.&#xD;
&#xD;
        Patients who are receiving:&#xD;
&#xD;
          -  Antiretroviral therapy, including nucleoside analogs, non-nucleoside reverse&#xD;
             transcriptase inhibitors, protease inhibitors or investigational antiretroviral&#xD;
             agents.&#xD;
&#xD;
          -  Interferon or interleukin therapy, aminoglycoside antibiotics, amphotericin B,&#xD;
             cidofovir, diuretics, foscarnet, ganciclovir, itraconazole, fluconazole, ketoconazole&#xD;
             (topical allowed), isoniazid, rifampin, rifabutin, clarithromycin, azithromycin,&#xD;
             systemic chemotherapeutic agents, systemic corticosteroids, other agents with&#xD;
             significant nephrotoxic potential, other agents that may inhibit or compete for&#xD;
             elimination via active renal tubular secretion (probenecid) and other investigational&#xD;
             agents.&#xD;
&#xD;
        Within 2 weeks prior to entry:&#xD;
&#xD;
          -  Antiretroviral therapy, including nucleoside analogs, non-nucleoside reverse&#xD;
             transcriptase inhibitors, protease inhibitors or investigational antiretroviral&#xD;
             agents.&#xD;
&#xD;
          -  Interferon or interleukin therapy, aminoglycoside antibiotics, amphotericin B,&#xD;
             cidofovir, diuretics, foscarnet, ganciclovir, itraconazole, fluconazole, ketoconazole&#xD;
             (topical allowed), isoniazid, rifampin, rifabutin, clarithromycin, azithromycin,&#xD;
             systemic chemotherapeutic agents, systemic corticosteroids, other agents with&#xD;
             significant nephrotoxic potential, other agents that may inhibit or compete for&#xD;
             elimination via active renal tubular secretion (probenecid) and other investigational&#xD;
             agents.&#xD;
&#xD;
        Active drug or alcohol abuse as demonstrated by a positive screening test for drugs of&#xD;
        abuse (except marijuana or drugs used for medical indications), or substance abuse&#xD;
        considered sufficient to hinder patient compliance.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>San Francisco Gen Hosp / AIDS Program</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins Univ</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 1999</verification_date>
  <study_first_submitted>November 2, 1999</study_first_submitted>
  <study_first_submitted_qc>August 30, 2001</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 31, 2001</study_first_posted>
  <last_update_submitted>June 23, 2005</last_update_submitted>
  <last_update_submitted_qc>June 23, 2005</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 24, 2005</last_update_posted>
  <keyword>Placebos</keyword>
  <keyword>Anti-HIV Agents</keyword>
  <keyword>Adenine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tenofovir</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

